Chemours Q3 Net Sales Rise 3% to $1.54 Billion; Net Income Reaches $196 Million

Chemours reported Q3 2026 net sales of $1.54B, up 3% YoY, and net income of $196M, compared to $46M a year earlier. Adjusted EBITDA was $200M, and adjusted diluted EPS was $0.21. Growth in Titanium Technologies and Advanced Performance Materials was offset by weaker North American air-conditioning sales. The company also launched a new liquid-cooling portfolio and settled PFAS-related litigation.

Original reporting
Published Nov 2, 2026, 9:43 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Nov 2, 2026, 9:53 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
Chemours Q3 Net Sales Rise 3% to $1.54 Billion; Net Income Reaches $196 Million — source image
Decision brief

The 30-second read

$CCBullishMed
01

Why it matters

Net sales growth plus a large jump in net income and adjusted EPS/EBITDA can re-rate near-term earnings power, while segment commentary flags where demand is improving versus where it is still soft.

02

Market read

A fresh quarterly earnings print with segment-level demand and pricing drivers, plus legal settlement context, provides actionable information for positioning into subsequent quarters.

03

What to watch

The PFAS litigation settlement and the Kuan Yin property sale are mentioned but without quantified financial impact; traders may discount the earnings quality until the filings clarify any one-time effects.

Relevance 8/10Novelty 8/10Timing: after-hours earnings release (published 2026-11-02 21:43 UTC)

Background

The piece summarizes Chemours’ Q3 2026 results and operational updates, including segment performance and legal resolution language from an SEC 8-K.

Company-level read

Ticker impact

$CCBullishMedium confidence
Context

Chemours (CC) reported Q3 2026 net sales up 3% to $1.54B and net income rising to $196M, with segment drivers and a PFAS litigation settlement.

Expected impact

Likely upward bias as the market digests higher net income and adjusted EPS/EBITDA, offset by caution on weaker North American stationary air-conditioning aftermarket.

Evidence & confidence

The article provides concrete quarterly financials (sales, net income, adjusted EPS, adjusted EBITDA) plus segment commentary and a PFAS settlement, which together can move positioning into the next quarter.

Market effects

Titanium dioxide (TiO2) pricing and specialty materials demand are highlighted as key swing factors, which can influence sentiment across specialty chemicals and coatings supply chains.

North America stationary air-conditioning aftermarket softness is explicitly cited, suggesting regional end-market divergence within industrial chemicals.

Asia-Pacific (ex-China) volume strength and Latin America demand support a more global demand narrative for specialty materials.

Counterpoint

The headline profitability improvement may be partly offset by segment-level weakness in Thermal & Specialized Solutions, so the market may fade the move if guidance or demand visibility is limited beyond this quarter.

Key entities

  • Chemours Co

    Reported Q3 2026 net sales of $1.54B (+3% YoY) and net income of $196M, with segment drivers and a PFAS litigation settlement.

Related articles

$CCMed

The Chemours Co (CC) (Q3 2026) Earnings Call Highlights: Pricing Momentum and AI-Driven

The Chemours Co (CC) reported Q3 2026 earnings, highlighting pricing momentum and AI-driven demand. The company lowered its free cash flow conversion outlook to 15%-20%, citing legal settlements and working capital timing. Q4 net sales for TSS are expected to decline 15%-20% due to seasonality, with adjusted EBITDA of $105-$115 million. TT's adjusted EBITDA is guided to $60-$65 million.

$CCMed

Canton CC Rises 4% After SEC Staff No-Action Letter

Canton Coin (CC) rose 4% after the SEC staff issued a no-action letter viewing it as a 'digital commodity.' The letter is not binding but indicates the SEC may not pursue enforcement action over CC's issuance under described conditions. CC traded at $0.098, down 4.2% over the past week, according to CoinMarketCap.

$CCMedAI 8/10

Chemours (CC) Q3 2026 Earnings Call Transcript

Chemours (CC) reported Q3 2026 adjusted EBITDA of $200M, above guidance. TSS saw lower demand for Opteon blends, while TT and APM exceeded expectations. The company settled litigation with North Carolina and received final approval for a New Jersey consent order. Guidance for Q4 includes seasonal declines in sales and EBITDA for TSS and TT, with APM showing growth in Performance Solutions.

$CCHigh

What Chemours (CC) Said on Its Q3 Earnings Call

Chemours (CC) expects Q4 net sales to decline in high-single-digit to low-teens range and adjusted EBITDA of $60M-$65M, citing seasonality and weaker demand. APM sales rose 26% YoY, driven by AI infrastructure demand, with Q4 sales expected to increase in low- to mid-teens range. TSS faces seasonal aftermarket softness, with Q4 sales expected to decline in high-teens to low-20% range. Full-year net sales are expected to increase about 2% compared with 2025, with adjusted EBITDA of $775M-$800M.

$CCMedAI 8/10

Chemours Q3 2026 slides: pricing gains offset seasonal headwinds

Chemours (CC) reported Q3 2026 earnings of $0.21 per share, missing estimates, on revenue of $1.54B. Adjusted EBITDA met high-end guidance at $200M, driven by pricing gains in Titanium Technologies and growth in Advanced Performance Materials. Stock initially dropped 2.73% but recovered 1.9% after-hours. Net sales rose 3% YoY, while net leverage improved to 4.3x.